Top in rheumatology: FDA action on tanezumab, unapproved CBD products
Click Here to Manage Email Alerts
The FDA’s Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee denied Pfizer’s risk mitigation proposal for its osteoarthritis drug tanezumab. A recap of the hearing was the top story in rheumatology last week.
Also last week, the FDA issued warning letters to companies illegally marketing unapproved products containing cannabidiol. The agency alleged that these products are being marketed in violation of the Federal Food, Drug and Cosmetic Act.
Read these and more top stories in rheumatology below:
FDA panel rejects Pfizer's tanezumab for osteoarthritis pain over risk-benefit doubts
A pair of FDA advisory committees has rejected a risk mitigation proposal from Pfizer for its NGF-blocker tanezumab, stating it would fail to ensure the drug’s benefits outweigh its risks for patients with osteoarthritis. Read more.
FDA warns against 'unapproved CBD products' touting arthritis pain relief
The FDA has issued warning letters to Honest Globe Inc. and Biolyte Laboratories LLC for allegedly illegally marketing unapproved, over-the-counter drugs labeled as containing cannabidiol for arthritis and other pain indications. Read more.
MIS-C mystery persists even as rheumatologists' arsenal proves key to treatment
As physicians around the world scrambled throughout early 2020 to respond to the exploding COVID-19 pandemic, the one promising development appeared to be that children were at relatively low risk compared with adults. Read more.
Anxiety, depression reduce odds of achieving minimal disease activity in PsA
Anxiety and depression symptoms reduce the likelihood of achieving sustained minimal disease activity in psoriatic arthritis, according to data published in Arthritis Care & Research. Read more.
Genicular artery embolization 'highly effective' in reducing knee OA pain
Genicular artery embolization is safe and “highly effective” in reducing symptoms of moderate-to-severe knee osteoarthritis in patients who have been unresponsive to other conservative therapy, according to data. Read more.